Clinical Trial Update: Effect of Icosapent-ethyl Ester (IPE) to Reduce the Residual Risk Cardiovascular Disease. [NA]

View source ↗

Summary

This clinical trial update reports that a study evaluating icosapent-ethyl ester (IPE) to reduce residual cardiovascular risk in patients with atherosclerotic c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease

Drugs mentioned

• Icosapent-ethyl ester (icosapent ethyl)

Snippet

Sponsor: University of Sao Paulo | Conditions: Atherosclerosis Cardiovascular Disease | NA | Status: NOT_YET_RECRUITING